Sanofi India (500674) Q4 2025 earnings summary

Executive summary

• Year marked by significant transformation, including business model modernization, strategic demerger of the Consumer Healthcare business effective June 1, 2024, and a focus on sustainable, profitable growth in insulin and legacy partnerships.

• Diabetes franchise maintained leadership, with Lantus holding 31% market share and Toujeo achieving double-digit growth, supported by digital and AI-enabled initiatives.

• Audited financial results for 2025 were approved with an unmodified opinion from statutory auditors.

• Board recommended a total dividend of ₹123 per share for 2025, subject to shareholder approval.

• Appointment of new directors and resignation of a non-executive director were announced.

Financial highlights

• Revenue from operations for 2025 was ₹18,374 million, down from ₹20,132 million in 2024; total income was ₹18,571 million, down 9% year-over-year.

• Net profit from continuing operations for 2025 was ₹3,267 million, up from ₹3,137 million in 2024.

• Profit before tax and exceptional items for FY 2025 was ₹4,720 million, up 1% year-over-year.

• Operating expenses reduced by 17% for both the quarter and full year, reflecting strategic cost management.

• Earnings per share for 2025 was ₹141.85; proposed dividend per share at ₹123, up 5% from 2024.

Outlook and guidance

• Partnership business expected to stabilize by end of 2026, with quarterly fluctuations due to inventory and stock agreements.

• No new product launches planned for 2026; focus remains on maximizing current diabetes and insulin portfolio, with Soliqua and Toujeo expansion in public sector.

• Continued investment in R&D, digital solutions, and assessment of new Labour Codes' impact on employee benefits.